Exelixis shares gain on launch of Phase III trial

There's a considerable amount of attention being focused on Exelixis' move to launch a late-stage study of XL184. The Motley Fool says that the first stage of the trial should be wrapped by the end of next year, giving investors a key point to decipher the drug's commercial prospects. That could mean an approval and marketing as early as 2010, but the Fool is quick to note that that is only a very rough timeline.

- see Exelixis' release
- read the analysis from Motley Fool

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.